在完成对第一组受试者的安全性评估并获得良好反馈后,临床研究委员会已正式批准Skye Bioscience Inc.启动其研究项目的第二组患者入组工作。该组别将采用600毫克的静脉注射剂量方案。这一决定标志着该药物临床开发进程向前迈出了关键一步。
在完成对第一组受试者的安全性评估并获得良好反馈后,临床研究委员会已正式批准Skye Bioscience Inc.启动其研究项目的第二组患者入组工作。该组别将采用600毫克的静脉注射剂量方案。这一决定标志着该药物临床开发进程向前迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.